SYN - Synthetic Biologics, Inc.

NYSE American - Nasdaq Real Time Price. Currency in USD

Synthetic Biologics, Inc.

9605 Medical Center Drive
Suite 270
Rockville, MD 20850
United States
301-417-4364
http://www.syntheticbiologics.com

SectorHealthcare
IndustryBiotechnology
Full Time Employees24

Key Executives

NameTitlePayExercisedYear Born
Mr. Steven A. ShallcrossInterim CEO, CFO, Sec., Treasurer & Sec.601.18kN/A1961
Dr. Joseph A. SlimanChief Medical OfficerN/AN/A1973
Vincent I. PerroneDirector of Corp. CommunicationN/AN/AN/A
Dr. Michael Kaleko M.D., Ph.D.Sr. VP of R&DN/AN/AN/A
Dr. Raymond D. Stapleton Jr., Ph.D.Sr. VP of ManufacturingN/AN/AN/A
Amounts are as of December 31, 2016 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Synthetic Biologics, Inc., a late-stage clinical company, develops therapeutics designed to preserve the microbiome to protect and restore the health of patients. Its lead product candidates are in Phase III development, such as SYN-004 that is designed to protect the gut microbiome from the effects of commonly used intravenous (IV) beta-lactam antibiotics for the prevention of C. difficile infection, overgrowth of pathogenic organisms, and the emergence of antimicrobial resistance; and SYN-010 which is intended to reduce the impact of methane-producing organisms in the gut microbiome to treat an underlying cause of irritable bowel syndrome with constipation. The company's preclinical products include an oral formulation of the enzyme intestinal alkaline phosphatase to treat local GI disorders and systemic diseases; monoclonal antibody therapies for the prevention and treatment of pertussis; and novel discovery stage biotherapeutics for the treatment of phenylketonuria. Synthetic Biologics, Inc. has collaborations with Intrexon Corporation, The University of Texas at Austin, and Cedars-Sinai Medical Center. The company was formerly known as Adeona Pharmaceuticals, Inc. and changed its name to Synthetic Biologics, Inc. in February 2012. Synthetic Biologics, Inc. was founded in 2001 and is headquartered in Rockville, Maryland.

Corporate Governance

Synthetic Biologics, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.